BPMC - Blueprint Medicines reports data from systemic mastocytosis program at AACR 2021

Blueprint Medicines (BPMC) announces data from its systemic mastocytosis ((SM)) program at AACR Annual Meeting 2021.The presentations focus on data of Ayvakit (avapritinib) in advanced SM, the impact of Ayvakit on skin manifestations of SM, and Phase 1 trial data for BLU-263.Highlights from Phase 2 PATHFINDER Trial75% (95% CI: 57%, 89%) of patients had a confirmed response, which was defined as complete remission with full or partial recovery of peripheral blood counts (CR/CRh), partial remission or clinical improvement.The median time to response was two months, and all responses were ongoing at a median follow-up of 10.4 months.The CRh rate was 19%, with a median time to CRh of 5.6 months. These results show that responses deepened over time at a rate consistent with the EXPLORER trial.In new patient-reported outcomes data, Ayvakit showed a statistically significant reduction in total symptom score after 40 weeks (p<0.001).Treatment with AYVAKIT resulted in robust improvements in

For further details see:

Blueprint Medicines reports data from systemic mastocytosis program at AACR 2021